Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H. Wilson(National Institutes of Health), Rod Humerickhouse(Abbott Fund), Sari H. Enschede(AbbVie (United States)), Yue Cui(Abbott (United Kingdom)), John P. Leonard(New York University), Anil Tulpule(University of Southern California), Kieron Dunleavy(National Cancer Institute), John F. Gerecitano(Memorial Sloan Kettering Cancer Center), Andrew Krivoshik(Abbott (United Kingdom)), Ann S. LaCasce(Otsuka (Japan)), Yi‐Lin Chiu(National Defense University), Steven W. Elmore(AbbVie (United States)), Myron S. Czuczman(Roswell Park Comprehensive Cancer Center), Saul H. Rosenberg(Abbott Fund), Owen A. O’Connor(Virginia Cancer Institute), Todd Busman(Abbott Fund), Hao Xiong(Shanghai Jiao Tong University)
Cited by 852
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k